| Oct 21 |
Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference
|
| Oct 17 |
Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement
|
| Oct 16 |
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024
|
| Oct 14 |
New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support
|
| Oct 11 |
New to the Street Announces Exclusive Bloomberg Lineup for Saturday October 12 at 6:30 PM EST
|
| Oct 11 |
New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST
|
| Sep 26 |
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues
|
| Sep 24 |
Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
|
| Sep 9 |
New to the Street Announces Its Five Corporate Interviews, Airing Episode 599 on the Fox Business Network, Tonight Monday, September 9, 2024, at 10:30 PM PT September 9, 2024 09:15 ET
|
| Aug 26 |
ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference
|
